Stabilization of prolactin receptor in breast cancer cells

Oncogene

Volumn 25, Issue 13, 2006, Pages 1896-1902

  Li, Y ^a   Clevenger, C V ^b   Minkovsky, N ^a   Kumar, Kgs ^a   Raghunath, P N ^a   Tomaszewski, J E ^a   Spiegelman, V S ^c   Fuchs, S Y ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b NORTHWESTERN UNIVERSITY   (United States)

^c UNIVERSITY OF WISCONSIN MADISON   (United States)

Author keywords

TrCP; Breast cancer; E3 ligase; Prolactin; Receptor; Ubiquitin

Indexed keywords

BETA TRANSDUCIN REPEAT CONTAINING PROTEIN; PROLACTIN; PROLACTIN RECEPTOR; SERINE; UBIQUITIN PROTEIN LIGASE;

ARTICLE; BREAST CANCER; BREAST EPITHELIUM; CANCER CELL; CANCER TISSUE; CONTROLLED STUDY; CORRELATION ANALYSIS; EMBRYO; HUMAN; HUMAN CELL; HUMAN TISSUE; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; PROTEIN STABILITY; TUMOR CELL;

BETA-TRANSDUCIN REPEAT-CONTAINING PROTEINS; BREAST; BREAST NEOPLASMS; DOWN-REGULATION; EPITHELIAL CELLS; FEMALE; HUMANS; KIDNEY; PHOSPHORYLATION; RECEPTORS, PROLACTIN; TUMOR CELLS, CULTURED; UBIQUITIN;

EID: 33645313745     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/sj.onc.1209214     Document Type: Article

References (24)

1. Canbay E, Degerli N, Gulluoglu BM, Kaya H, Sen M, Bardakci F. (2004). Curr Med Res Opin 20: 533-540.
2. Cartun RW, Pedersen CA. (1989). J Histotechnol 12: 273-280.
3. Clevenger CV. (2004). Am J Pathol 165: 1449-1460.
4. Clevenger CV, Chang WP, Ngo W, Pasha TL, Montone KT, Tomaszewski JE. (1995). Am J Pathol 146: 695-705.
5. Clevenger CV, Furth PA, Hankinson SE, Schuler LA. (2003). Endocr Rev 24: 1-27.
6. Das R, Vonderhaar BK. (1997). J Mammary Gland Biol Neoplasia 2: 29-39.
7. Diehl JA. (2002). Cancer Biol Ther 1: 226-231.
8. Glasow A, Horn LC, Taymans SE, Stratakis CA, Kelly PA, Kohler U et al. (2001). J Clin Endocrinol Metab 86: 3826-3832.
9. Goffin V, Bernichtein S, Touraine P, Kelly PA. (2005). Endocr Rev 26: 400-422.
10. Harvey PW. (2005). J Appl Toxicol 25: 179-183.
11. Kim H, Farris J, Christman SA, Kong BW, Foster LK, O'Grady SM et al. (2002). Biochem J 365: 765-772.
12. Kline JB, Rycyzyn MA, Clevenger CV. (2002). Mol Endocrinol 16: 2310-2322.
13. Li Y, Kumar KG, Tang W, Spiegelman VS, Fuchs SY. (2004). Mol Cell Biol 24: 4038-4048.
14. Meng J, Tsai-Morris CH, Dufau ML. (2004). Cancer Res 64: 5677-5682.
15. Perks CM, Keith AJ, Goodhew KL, Savage PB, Winters ZE, Holly JM. (2004). Br J Cancer 91: 305-311.
16. Polakis P. (1999). Curr Opin Genet Dev 9: 15-21.
17. Polakis P. (2000). Genes Dev 14: 1837-1851.
18. Reynolds C, Montone KT, Powell CM, Tomaszewski JE, Clevenger CV. (1997). Endocrinology 138: 5555-5560.
19. Rose-Hellekant TA, Arendt LM, Schroeder MD, Gilchrist K, Sandgren EP, Schuler LA. (2003). Oncogene 22: 4664-4674.
20. Spiegelman VS, Tang W, Chan AM, Igarashi M, Aaronson SA, Sassoon DA et al. (2002). J Biol Chem 277: 36624-36630.
21. Tang W, Li Y, Yu D, Thomas-Tikhonenko A, Spiegelman VS, Fuchs SY. (2005). Cancer Res 65: 1904-1908.
22. Tworoger SS, Eliassen AH, Rosner B, Sluss P, Hankinson SE. (2004). Cancer Res 64: 6814-6819.
23. Wennbo H, Gebre-Medhin M, Gritli-Linde A, Ohlsson C, Isaksson OG, Tornell J. (1997). J Clin Invest 100: 2744-2751.
24. Wennbo H, Tornell J. (2000). Oncogene 19: 1072-1076.